- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Whole-body PET/CT scans take on colon cancer, other new challenges
A whole-body PET/CT scan can be used to stage and further pinpoint cancers spotted on optical colonoscopy, a research team for Essen University reported Monday. The team also reported that PET/CT scans may be useful in restaging recurrent breast cancer.
A whole-body PET/CT scan can be used to stage and further pinpoint cancers spotted on optical colonoscopy, a research team for Essen University reported Monday. The team also reported that PET/CT scans may be useful in restaging recurrent breast cancer.
The papers were among several evaluating the use of PET/CT in advanced applications. Generally, they reported good results. One study that evaluated whole-body MR and whole-body PET/CT for imaging lymph node and distant metastases secondary to melanoma gave both modalities relatively low marks for sensitivity, however, resulting from their inability to spot small lesions.
The whole-body colonoscopy study included 14 patients and was designed to evaluate whether the PET/CT scan could be successfully integrated with a dedicated CT and an optical colonoscopy exam. The researchers concluded that it could and that it allows accurate TNM staging in patients with colorectal cancer.
PET/CT colonography detected 18 of 19 lesions identified by conventional colonoscopy, missing only one flat lesion. Six extracolonic tumor sites were also detected with the PET/CT scan. Based on the imaging findings, 11 patients were treated surgically, and three by chemotherapy. Histologic data showed that imaging revealed correct T-stage in eight of the 11 patients and correct N-stage in nine patients.
The breast cancer study evaluated 58 patients suspected of recurrent breast cancer. All underwent whole-body PET/CT scans with FDG. Correct TNM tumor stage identification varied with modality:
- 93% with PET/CT
- 90% with PET and CT scans reviewed side by side
- 84% with CT alone
- 79% with PET alone
The study of malignant melanoma patients was also conducted by Essen University. It included data from 31 patients who had whole-body contrast MR scans and whole-body FDG-PET/CT scans. PET/CT had a sensitivity of 50% and a specificity of 100% for N-stage cancers, compared with 33.3% and 100%, respectively, for MR. PET/CT had a sensitivity of 37.5% and a specificity of 95.4% for M-stage cancers, compared with 12.5% and 95.5%, respectively, for MR.
An analysis of the data showed that the sensitivity figures were pulled down by missed cancers 7 mm or smaller, said Dr. Florian Vogt, who presented the data.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
